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EXECUTIVE SUMMARY Optimizing Preventive Strategies and Malaria Diagnostics to Reduce the Impact of Malaria on U.S. Military Forces

DoD Malaria Stakeholder Meeting
30-31 May 2012
Despite the availability of effective prevention measures and a long organizational history of fighting the disease, malaria remains a threat to U.S. forces and their operations. 1 These effective prevention practices and protective measures are not uniformly implemented to avert disease in the DoD. The Medical Surveillance Monthly Report documents the ever-increasing number of malaria cases acquired in Afghanistan-91 cases in 2011 -the greatest number in the last nine years. 2 Malaria consistently ranks as the most important infectious disease threat to the U.S. military 3 and is a significant force health protection (FHP) issue before, during and after deployments. Participants represented a wide array of DoD organizations, including representatives from OSD/HA, geographical Combatant Commands, public health and headquarters commands of the U.S. Army, Air Force, Navy, and Marine Corps, along with members of the operational, public health, preventive medicine, infectious disease, entomology, pest management, education and training, laboratory, materiel and acquisitions, and research and development communities. This year's DoD Malaria Stakeholder meeting was built upon the success and progress made from last year's 2011 DoD Malaria Stakeholder meeting. Significant discussion at that venue addressed: revising malaria chemoprophylaxis policy to potentially advocate for greater Malarone® use in high-risk areas; endorsing collaboration between the overseas laboratories and the training and education commands to improve malaria microscopy slide sets and training; identifying the need for more clinical decision support tools for deployed providers, specifically creating a malaria clinical practice guideline and diagnostic algorithm; and, pursuing better educational materials and products to improve compliance with personal protective measures (PPM). Issues highlighted as warranting further examination included having expeditionary diagnostic capability in theater, identifying a common location for the archival of DoD malaria resources, and examining the policy and practices surrounding primaquine use in U.S. forces returning from malaria endemic regions.
This 2-day 2012 Malaria Stakeholder meeting included didactic lectures and expert panels by DoD and academic subject matter experts, followed by frank open discussions. To address the many issues identified during last year's DoD Malaria Stakeholder meeting, this meeting's objectives were to:
 Provide an update regarding current malaria mitigation efforts in support of the Combatant Commands;
 Assess operational challenges in malaria diagnostics;
 Identify potential solutions to optimize malaria diagnostic modalities;
 Continue collaborations for the development of clinical decision support tools and inventory of DoD malaria resources;
 Clarify issues regarding primaquine terminal chemoprophylaxis. Setting the stage for this forum was an account from Liberia demonstrating successful malaria prevention interventions used in support of Operation Onward Liberty. Using a combination of known strategies and the incorporation of innovative means of accountability-leveraging a text message reporting system to ensure chemoprophylaxis compliance-malaria cases within the unit were eliminated. This vignette highlighted the success that is possible when leadership, accountability, and preventive medicine principles are effectively employed in a malaria-endemic deployed setting.
This stakeholder forum addressed topics of particular relevance to the DoD and force health protection, to include: primaquine chemoprophylaxis, clinical decision support tools and knowledge management, and malaria rapid diagnostic tests (RDTs). The forum also included a comprehensive recap of the progress made since last year's forum, including updates of the current DoD chemoprophylaxis policy, malaria clinical practice guidelines, and current efforts to ensure PPM compliance in troops. Areas of particular interest included:
1) Primaquine policy:
Stakeholders agreed that presumptive antimalarial relapse therapy (PART) should continue to be a component of FHP but must be a risk-based decision. The CDC has determined that 30 mg primaquine for 14 days is more efficacious than the current FDAapproved 15 mg daily dose. This is problematic since the DoD is constrained by FDA dosing recommendations for FHP policy. Future efforts need to explore available options to provide allowance for the 30 mg dosing regimen, which will then dictate guidance, policy and clinical decision support tools.
2) Clinical Decision Support Tools & Knowledge Management:
The need for a common location to archive DoD malaria resources was previously identified. 
Proceedings of the 2012 DoD Malaria Stakeholder Meeting
Introduction and Updates
The workshop commenced with "Introductory Remarks" from CAPT Kevin Russell (Director, Armed Forces Health Surveillance Center (AFHSC)) who highlighted the importance of malaria to deployed troops and the importance of convening malaria stakeholders in a face-to-face fashion. Following CAPT Russell's opening remarks, Dr. George P. Taylor (Deputy Assistant Secretary for Force Health Protection and Readiness (FHP&R)) provided the "Welcoming Address" which focused on the tremendous impact of malaria on the Department of Defense, preventing malaria in deployed troops, and appropriately treating cases that occur.
Capt William Scott (Nellis AFB) set the stage for the 2012 DoD Malaria Stakeholder Meeting by discussing his experiences "Optimizing Preventive Strategies on the Front Lines." As chief medical officer assigned to Operation Onward Liberty, Capt Scott shared his successes and challenges in malaria prevention in Liberia. Upon his arrival, malaria prophylaxis accountability consisted of a paper checklist posted in the gym where Service members affirmed whether they had taken their daily prophylaxis. The 12 malaria cases in the previous calendar year reflected the haphazard emphasis on, and the lack of compliance with, malaria prevention. In light of this less-than-ideal system, Capt Scott initiated several operational changes, to include random bednet checks, permethrin-treated uniforms, mandatory DEET distribution, malaria quizzes at all-hands meetings, and distribution of malaria prevention handouts during troop in-processing.
Additionally, a text messaging system was introduced and was a notable success. Service members were required to report daily compliance with malaria chemoprophylaxis to the general medical officer (GMO) or senior medical officer on duty. This texting system was particularly helpful during mobilities, when Service members were geographically dispersed or remote. Capt Scott focused on leveraging troop buy-in and incentivized his units to garner compliance. However, he was quick to emphasize that technological solutions are not always the answer and that many of his interventions were low tech and merely provided leadership and accountability. As evidence of the effectiveness of his interventions, no cases of malaria occurred during Capt Scott's tenure.
CDR Annette Von Thun (AFHSC) provided a synopsis and "Update from the 2011 DoD Malaria Stakeholder Meeting". She highlighted the main outcomes and accomplishments from last year's meeting, the interval progress that had been made, and some of the remaining items that intended to be addressed by this current meeting's curriculum. Results of the mini-surveys and evaluations were shared and provided a framework for the current meeting's discussions. A full review of these topics can be found in the Proceedings of the 2011 DoD Malaria Stakeholder Meeting. by the AFHSC, and the limitations associated with administrative data. She noted that cases of malaria in the DoD had increased over the past three years, with Plasmodium vivax (P. vivax) comprising the majority of cases for which species-specific detail was documented. Most cases in 2011 were in the active component (87.1%), in the Army (79.8%) and male (97.6%), with the 20-24 year age group most at risk. The largest number of presumed malaria cases in 2011 came from Afghanistan (91 cases), followed by Africa (24 cases). Alternative and more inclusive case definitions have been considered by AFHSC and were recently published in the Military Surveillance Monthly Report (MSMR).
2 LTC Teneza concluded by highlighting that malaria is still an issue for the U.S. Armed Forces, which makes having the capability to prevent, recognize, and treat malaria of paramount importance.
COL Scott Stanek (ASD/HA) provided an update on the status to the "DoD Chemoprophylaxis Policy" that was drafted at last year's meeting which proposed: Malarone® as the drug of choice for high-transmission settings; Malarone® or doxycycline as equivalent drugs of choice for low-transmission settings; Malarone® as the preferred chemoprophylaxis agent for short-term deployments; and directly observed therapy in high-risk environments. The draft policy has been routed to the Services for comment and was briefed to the Force Health Protection Integration Council in July 2012. The current DoD policy has been criticized for being piecemeal and out of date. The most recent guidance (HA Policy 09-017) addresses concerns about mefloquine and identifies doxycycline as the drug of choice; however, healthcare providers frequently express frustration that access to Malarone® is often restricted by their pharmacy departments due to cost-concerns and the lack of policy supporting its use.
3 COL Stanek proposed a Quality Assurance Review to assess how the Services are implementing current chemoprophylaxis policy and screening for mefloquine suitability. Consistent and standardized chemoprophylaxis documentation is needed and there are concerns that the Services are not adequately screening or complying with the mefloquine policy requirements.
COL Colin Ohrt of the Walter Reed Army Institute of Research (WRAIR) presented an update on "Generic Malarone® Availability." Glenmark Pharmaceuticals recently won the right to market exclusivity for atovaquone-proguanil (ATP, generic Malarone®) for a duration of six months. Two other Indian companies are producing and marketing generic ATP, Cipla and Dazzle. Glenmark is a non-Trade Agreement Act company, and therefore the DoD cannot purchase from Glenmark; however, COL Ohrt pointed out that, despite the reduction in price that often accompanies a generically-branded medication, the DoD has a better financial agreement in place with GlaxoSmithKline for Malarone®.
The larger issue that arises with the production of ATP in generic form is the ability of the drug to become more ubiquitous in endemic areas due to its lowered cost. Medicines for Malaria Venture has stated that ATP could be available for as little as 25 cents a dose. Although the lowered cost is clearly advantageous for individuals seeking treatment, it could become a problem if not administered properly, particularly in malaria endemic countries. Substandard or fake ATP circulating in endemic 7 countries, or ATP not taken as directed, could induce point mutations in the malaria parasite potentially resulting in parasite resistance and rendering ATP ineffective. It was noted that many of these countries rely heavily on tourism as a source of revenue, and therefore should be invested in maintaining the pharmacological success of ATP as an anti-malarial agent; however, neither the DoD nor, in many cases, the endemic countries themselves have any ability to affect the development of ATP resistance.
CAPT Steven Rankin of the Armed Forces Pest Management Board (AFPMB) provided an update on "Personal Protective Measure (PPM) compliance and AFPMB Initiatives". CAPT Rankin's presentation focused on enhancing PPM compliance through the utilization of new technologies, particularly given the technological aptitude of our younger Services members. AFPMB is collaborating with the Telemedicine & Advanced Technology Research Center (TATRC) and Africa Command (USAFRICOM) to develop a new application for retraining troops deploying to malarious regions of USAFRICOM. Given the popularity of smart phones, web links and video clips, CAPT Rankin indicated that applications for Medical Stability Operations are being developed. Such applications could provide easily-accessible means for training young troops on the importance of PPM compliance. In addition to smart phone applications, AFPMB is meeting with the Defense Media Activity (DMA) to discuss the possibility of producing PPM infomercials to run on the Armed Forces Network (AFN) for Service members and dependents overseas.
Unable to attend in person, MAJ Jacob Johnson at U.S. Army Medical Research Unit Kenya (USAMRU-K) provided an update via telephone on the "GEIS Malaria Surveillance Steering Committee's Diagnostics Training Initiative." MAJ Johnson noted that this initiative is a multi-faceted program that encompasses three core areas: (1) training, (2) quality systems, and (3) reference materials. MAJ Johnson highlighted training accomplishments since 2004 noting that the Kisumu Malaria Diagnostics Center (MDC) has taught 62 microscopy courses, trained 1,134 laboratory technicians, trained and mentored over 20 facilitators, and has established three malaria microscopy training centers. As a result of preceding Malaria Stakeholder meetings, the MDC is coordinating with many of the other DoD research labs preparing standardized, validated malaria blood films (slides). These slides will be utilized by the DoD and host nation partners for training, testing, research, and quality control. The MDC is working with the Army Medical Department (AMEDD) to incorporate these malaria slide sets into their medical education curriculum. Additionally, MDC is piloting the production of dried blood tubes for quality control of rapid diagnostic tests (RDTs) in resource-limited and combat settings.
LTC Paul Mann (AMEDD) provided an "Update on Malaria Microscopy in the AMEDD." He noted that senior enlisted laboratory technicians received initial training in malaria microscopy during Medical Laboratory Technician (MLT) training. This training is considered "entry-level" and is insufficient to maintain competency in diagnostic malaria microscopy. The lack of malaria training was also noted to be an issue for incoming laboratory officers, particularly those trained in the civilian sector, since civilian universities do not teach the breadth and depth of tropical medicine that the military requires of its medics, laboratorians, and clinicians.
A multi-pronged approach is being initiated to address the current gap in malaria microscopy, including field trials of fluorescent microscopy (QBC ParaLens and F.A.S.T.); educating the direct accession lab officers during Officer Basic Course; engaging the medical laboratory specialists in familiarization training during MLT phase II; and creating web-based and DVD/CD training and sustainment packages. To this end, a diagnostics slide set was sent from the MDC and is being digitized onto a DVD to enable deployed personnel access to malaria diagnostic aids.
Dr. Refaat Hanna (USAFRICOM) provided an update on the "East-Africa Malaria Task Force (E-AMTF)." Dr. Hanna gave an overview of the formation of the E-AMTF, noting that the Task Force objectives at inception included defining the necessary components for an effective malaria prevention program; defining standards against which each nation may identify critical needs; and defining additional programs for building health system capabilities and capacities. E-AMTF membership currently includes: Burundi, Kenya, Rwanda, Tanzania, Uganda, and South Sudan.
The inaugural E-AMTF meeting was held 7-8 December 2011 in Philadelphia, PA at the 60 th Annual American Society for Tropical Medicine and Hygiene Conference. Each African country representative presented the challenges related to their military malaria programs during peacetime and deployments and identified malaria as the number one threat to their respective militaries. Among the accomplishments at this meeting were the crafting and ratification of the E-AMTF charter and bylaws.
The second E-AMTF meeting took place in Dar es Salaam, Tanzania in July 2012. The participants created a road map prioritizing and addressed the issues identified by a thorough gap analysis that was conducted by the E-AMTF members' critique of their military malaria programs. Various DoD subject matter experts provided guidance to the E-AMTF. Additionally, the products and discussions that occurred in these DoD Malaria Stakeholder meetings (e.g., chemoprophylaxis policy, malaria surveillance, PPM training, malaria diagnostic and treatment resources) dovetailed with, and will serve to advance, the E-AMTF objectives.
CAPT Jason Maguire, representing the Armed Forces Infectious Disease Society (AFIDS), provided an update on the "New Malaria/Febrile Illness Clinical Practice Guidelines for the DoD." The creation of DoD malaria treatment guidelines was a task undertaken by AFIDS at the request of the 2011 Malaria Stakeholders to address the need for greater clinical decision support tools for deployed providers. CAPT Maguire emphasized that this product is a clinical practice guideline (CPG), not a policy, and noted that the AFIDS recommendations are predicated upon the Infectious Diseases Society of America's (IDSA) criteria for quality of evidence. The CPG addresses: pre-deployment preparations; malaria epidemiology; clinical presentation and the assessment of severity; diagnostic testing in the military environment; anti-malarial regimens to include first/second-line, species-specific, empiric and prophylaxis failure treatment recommendations. CAPT Maguire provided a draft algorithm for evaluation and initial management of febrile illness in non-immune individuals with recent or current exposure in a malaria endemic region [Appendix A]. The intent is to finalize comments and then submit this malaria CPG for publication, with plans for wide dissemination to DoD personnel thereafter. 9
Clinical Decision Support Tools and Knowledge Management
During the 2011 DoD Malaria Stakeholder Meeting, substantial discussion was devoted to determining an appropriate venue to make pertinent malaria information available pre-and postdeployment. In this context, Dr. Mary Vaeth and Mr. Stacy Tucker (DoD Deployment Health Clinical Center (DHCC)) were invited to provide an "Overview of www.PDHealth.mil, Web-Support for Deployment-Related Healthcare." The PDHealth website is managed by the DHCC and serves as a comprehensive source of information for healthcare providers, Service members, veterans, and families. Topics address deployment health concerns and conditions (including malaria), health-related aspects of the deployment process, risk communication, deployment-related research, healthcare services, and patient and family support services. The deployment support section includes webpages on predeployment, re-deployment, deployment health assessments, deployment-related exposures, and specific deployments by operation and by country/region.
A malaria webpage already exists within the PDHealth website and contains Tri-Service policies and directives, clinical guidance, fact sheets, education and training, and other related links on malaria. In addition to the general malaria information, the PDHealth website also contains a separate webpage dedicated to information on mefloquine. Discussion ensued regarding the utilization of PDHealth as the central Tri-Service repository of malaria information for Service members. Stakeholders appreciated that adopting PDHealth as the Tri-Service archive does not preclude individuals Services from posting information on their own Service's websites.
Stakeholders were supportive of using the PDHealth.mil website to centralize resources, and a breakout session further defined the mechanism to support this process. The group recommended the formation of a board of advisors who would meet annually or semi-annually to assure that the content of the website was up-to-date and encompassed the appropriate information. At a minimum, this board should include representation from the Combatant Commands (CCMDs), Service public health hubs, the Coast Guard (if interested), and USUHS (Department of Preventive Medicine and Biometrics). The process by which the information would be funneled to DHCC was not delineated, but the annual board would come together and provide feedback to the DHCC website manager. USAPHC was designated the advisory board lead and will ensure periodic site content reviews are conducted. The group agreed that, whenever possible, malaria-related documents should be posted on open websites to avoid difficult-toaccess CAC-enabled and AKO/DKO-restricted platforms.
Primaquine Chemoprophylaxis
Dr. Alan Magill of the Defense Advanced Research Projects Agency (DARPA) introduced the topic of "Primaquine Chemoprophylaxis Dilemmas." Primaquine is indicated for primary prophylaxis, radical cure, and as presumptive anti-relapse therapy (PART). PART is a treatment strategy unique to the U.S. military. Despite appearing the same under a microscope, P. vivax is a heterogeneous species and there are nuances between different strains that exhibit definite biologic differences in response to treatment, relapse pattern and frequency depending on where the infection was acquired. Two prototype P. vivax strains are Chesson (tropical) and Korean (temperate).
Current Centers for Disease Control and Prevention (CDC) recommendations for primaquine dosing are 30mg (base) for 14 days, but the U.S. Food and Drug Administration (FDA) has only approved 15mg (base) for 14 days. The questions remain: How much primaquine is enough primaquine, and does primaquine resistance really exist? Dr. Magill indicated that often drug failures are reported as resistance; however, given the biologic differences in the P. vivax parasite, sub-therapeutic dosing could be a larger factor than initially considered. Primaquine was approved in 1952, and the FDA has not changed its recommendations for primaquine dosing since the initial licensure of the drug, nor has it been in the pharmaceutical companies' self-interest to perform the necessary population-based studies to document this regimen's efficacy. Although it could be argued that the FDA merely regulates product manufacturing and the licensing of pharmaceuticals, (and therefore does not regulate the practice of medicine), the Presidential Executive Order 13139 [Appendix B] and DoD Instruction (DODI) 6200.02 [Appendix C] prohibit DoD from the off-label use of medications for force health protection (FHP) purposes.
Following Dr. Magill's primaquine primer, CAPT William Padgett (Headquarters Marine Corps) led a discussion of "Primaquine Chemoprophylaxis -Way Ahead." The group deliberated whether primaquine anti-relapse therapy should be part of a routine post-deployment regimen upon return from high-risk areas. This led to further discussion as to whether PART was an FHP issue, whether everyone leaving a malarious zone should be prescribed PART, or whether PART should be used with consideration given to the malaria species (P. vivax and P. ovale) present in any given malarious area.
In the subsequent breakout session, participants suggested that the DoD consider weight-based dosing and PART for engagements that require small numbers of troops. Stakeholders generated four cogent topics regarding PART. (1) Since the U.S. military is the only military that uses PART, substantial discussion centered on whether PART should be kept as a standard requirement. The group members felt strongly, particularly given the countries in which the U.S. Armed Forces serve, that PART needs to remain a key component of the U.S. military FHP plan. (2) Having determined that PART needed to remain a requirement in the U.S. military FHP plan, the group focused on the necessary parameters for integration into higher-level policy, noting that CDC guidance is not based on field military conditions, the number of bites experienced, or malaria cases known to have occurred in the unit. The group will explore clinical practice guidelines, algorithms, and lists of subject matter experts to support the decision making of a GMO when determining the execution of PART. (3) The dosing regimen for PART was further deliberated, noting that the current FDA approved dose was 15mg daily for two weeks, per the package insert, which conflicted with the CDC recommendation of 30mg daily for two weeks. Since FHP policy cannot officially endorse the off-label use of a medication, treatment with the higher dose of primaquine would only be permitted in the context of an individual patient-provider relationship. The group will further investigate the options available to allow for the consideration of 30mg dosing regimen. (4) No clear conclusions were reached on whether PART needs to be a stand-alone DoD policy, integrated into existing DoD malaria policy, pushed to the Services, or left to the CCMD Surgeon's discretion. Determining how to incorporate PART into DoD policy is largely dependent on the dosing regimen (30mg vs. 15mg) and how that regimen is approved (DoD-level vs. Service-level vs. CCMD-level).
Ultimately, the PART dosage change should be the main effort going forward, and will be the basis for all other PART policy changes.
Diagnostic Challenges
Maj Robert Holmes (USAFRICOM) presented on "Perceived Problems with Malaria Diagnostic Options in the Operational Environment." Maj Holmes underscored the difficulty in finding local practitioners with malaria expertise in African countries, and that to use a local microscopist who also doubles as the apothecary is a dubious practice. The DoD has the need for highly sensitive rapid diagnostic tests that can be used in an operational setting by non-clinicians. Currently the only FDAcleared RDT (BinaxNOW®) lacks sensitivity (especially for P. vivax), is not heat-stable, and its packaging does not meet field requirements (25-kit minimum). Additionally, it lacks an inherent positive control, is a moderate complexity test that requires a trained laboratorian in a Role 3 medical care facility, and the FDA requires microscopy for confirmatory testing of all specimens that test negative.
Maj Holmes' presentation segued into a larger panel discussion which addressed "Diagnostic Challenges: Perspectives from the Front Lines" and the malaria diagnostic issues that continue to be particularly problematic in the field. The panelists included CAPT Mark Malakooti (NAVAF), LTC Christine Lang (USASOC), LTC Laura Pacha (USAPHC), LCDR Jean-Paul Chretien (II MEF), Capt William Scott (Nellis AFB), and HMCM Mitchell Pearce (NECC). Participants debated the merits of the BinaxNOW® RDT and the practice of empirically treating patients if presenting with a febrile illness while deployed to a malarious region. The sensitivity of the test to heat degradation was a topic of discussion, as was the issue that BinaxNOW® RDTs only have one bottle of reagent per box of 25 kits, making the kit rather unwieldy for field operations.
Discussion arose regarding the distinction between Role 1 and Role 2 asset regulations. The FDA's regulations only apply to tests conducted inside the United States. Participants underscored the need for clarification on Level I vs. Level II products that could be purchased CONUS using Operations & Maintenance (O&M) funds and then placed overseas. The development of a simple algorithm to address febrile illness in malarious regions was proposed to provide young GMOs and medics a solution to the RDT sensitivity issue, noting that the consequences of erroneous treatment for presumed malaria are far less than the consequences of not treating for malaria, and that no matter how high the levels of parasitemia in the blood, a negative RDT result can never be completely trusted.
Addressing the theme of "Current research and development (R&D) Efforts Addressing Malaria Diagnostics," LTC Phil Smith of U.S. Army Medical Research & Materiel Command (USAMRMC) provided background on "MRMC's Decision Gate and the Materiel Development and Acquisition Process". He discussed medical product acquisition, how money is invested, how USAMRMC oversees the investment of product development money, and the assessment of whether developed products are meeting enduser needs. USAMRMC implements "Decision Gate," a management support framework that defines the medical product development lifecycle. Decision Gate helps identify, verify, and validate true materiel gaps; establishes a review process to ensure cost and schedule progress; helps ensure investments are made with a portfolio perspective; and facilitates engagement of all stakeholders.
In addition to Decision Gate, USAMRMC has created defined Biomedical Technology Readiness Levels (TRLs). TRLs provide a systematic way to assess and communicate to the Milestone Decision Authority (MDA) the maturity level of a particular technology and the maturity necessary for successful product advancement. BinaxNOW® falls within TRL 9, "Post-marketing studies/surveillance."
MAJ Tom Palys (WRAIR, Chair of the Military Infectious Diseases Research Program (MIDRP)
Integrated Process Team (IPT)) briefed on the "MIDRP Malaria Diagnostics Efforts." The mission of the MIDRP diagnostics program is to develop FDA-cleared RDTs or hospital-based diagnostic assays for naturally occurring infectious diseases of military importance. The program is executed by WRAIR, Naval Medical Research Center (NMRC), and the overseas laboratories (AFRIMS, USAMRU-K, NAMRU-6, NAMRU-3, and NAMRU-2). The Tri-Service Infectious Disease Threats to the U.S. Military Prioritization Panel has ranked 38 infectious disease threats, placing higher priority on those diseases that have no vaccine or prophylactic treatment, for which there is no available field-deployable diagnostic capability, and which have the greatest potential to hinder troop strength.
Over the last ten years, seven percent ($1.618 million) of MIDRP diagnostic funding has been directed to malaria diagnostics. From 2006 -2009, the MIDRP diagnostics program-in collaboration with AFRIMS-funded the species-specific malaria PCR assay for the Joint Biological Agent Identification and Detection System (JBAIDS). In 2007, with NMRC, the MIDRP diagnostics program provided support for a Multiplex RDT to identify fever causing pathogens in the blood, but the performance of this assay was deemed inadequate and funding was discontinued. Additionally, MIDRP funded a malaria speciesspecific loop-mediated isothermal amplification and oligoimmunochromatographic combination RDT. Although $155,000 was allocated for malaria diagnostics in 2012, no funds were designated for malaria diagnostics in 2013. So although malaria is currently the top infectious disease threat, USAMRMC has been focusing their efforts on other diseases since there is an existing FDA-cleared RDT product and medications available for both prevention and treatment. Continuing the theme of current R&D efforts in malaria diagnostics, COL Ohrt briefed meeting participants on "New Technologies for the Tracking of Malaria in Deployed Troops." COL Ohrt highlighted the novel technologies developed by Amethyst Technologies, Fio Corporation, and Johns Hopkins University Applied Physics Lab (JHU/APL). The Fio Corporation has developed a Smartreader that enables real-time quality improvement and tracking of malaria in deployed troops. The Smartreader is a device that can be programmed and calibrated to read RDTs and provide an automated diagnosis. Clinical data is then captured on the touch screen interface and can be electronically stored and/or mailed to a secondary reviewer. The JHU/APL Suite for Automated Global Electronic Biosurveillance (SAGES) initiative is a platform that allows for syndromic data to be collected and transmitted via smart phones. SAGES works particularly well in resource-limited areas. These technologies could be utilized to improve malaria surveillance and diagnosis in deployed troops or troops serving in areas with limited diagnostics and has already been implemented in Kenya and Cameroon for other comprehensive disease surveillance purposes.
Dr. Martina Siwek (Chemical Biological Medical Systems (CBMS)) presented a briefing on the "Next Generation Diagnostics System (NGDS)." CBMS is seeking replacement technology for JBAIDS which is to be phased out by 2017 with the expectation that malaria will be incorporated into its NGDS platform. The NGDS development strategy for the replacement of JBAIDS is an interagency effort that involves the development of both a deployable and a Service laboratory component.
The deployable component would ideally be a commercial, off-the-shelf (COTS), FDA-cleared diagnostic system with improved analytical capacity and operational suitability. The deployable component would have maximum potential for rapid and affordable future capability growth to support diagnostics, surveillance and environmental detection of biological threats. The Service lab component would leverage existing laboratory infrastructure and be capable of identifying emerging, enhanced, and advanced threats. The aim of the Service lab component is to reduce the time to novel pathogen discovery by supporting rapid diagnostics development on other NGDS components. Ideally, the Service lab component would provide robust, in-country analytical capability. Such a component would be capable of being forward deployed, have reach-back potential, and be able to be utilized in a contingency-response capacity. The next evolution would have advanced capabilities that include lowcomplexity diagnostics and surveillance (capable of being used in a Role 1 or 2 medical support capacity); be capable of chemical, radiological and toxin exposure diagnoses; contain pre-symptomatic diagnostics; and have novel pathogen discovery capabilities.
To provide additional information on future malaria diagnostic efforts, Dr. Brad Ringeisen (Defense Threat Reduction Agency (DTRA)) gave a presentation on the "DTRA 24-Month Diagnostic Device Challenge." The objective of the 24-month challenge is an interim demonstration at the OCONUS labs, of an informatics-based, bio-surveillance ecosystem linked to ubiquitous, selfadministered diagnostics capability. A "decision engine" is envisioned to use artificial intelligence to interpret data from the diagnostic system and return results with appropriate guidance to the individual. The decision engine will be leveraged to remove individual interpretation from the process to ensure accuracy, and will serve as the link between the diagnostics systems and the information management ecosystem.
Point-of-need diagnostic systems are proposed and will be developed for self-use or buddy care (Role 0) for use by non-medically trained Service members, with complexity akin to the home pregnancy test. Additionally, a Role 1 device for medics, corpsmen, and technicians will be engineered to provide forward medical care in the deployed environment. The 24-month challenge OCONUS field demonstrations are expected to perform in a real-world setting of endemic and/or epidemic diseases, and is planned to have FDA clearance and CLIA-waived status. The preliminary malaria clinical test sites for the 24-month challenge will include NAMRU-2 (Cambodia), USAMRU-K (Kenya), NAMRU-3 (Egypt) and Nigeria (WRAIR collaborative site).
Dr. Valerie D'Acremont of the Swiss Tropical and Public Health Institute telephonically provided a guest lecture on the "Robustness of Existing Malaria RDTs: Is Confirmatory Testing Necessary?" Dr. D'Acremont presented data from studies in Africa, Europe, and the United States regarding the sensitivity of RDTs versus the "gold standard" blood film microscopy for malaria diagnosis.
5 She noted that positivity rates can be partially explained by patients' parasitemia, which is dependent on many variables, including pre-existing host immunity against malaria. Comparing RDTs with microscopy as the gold-standard is generally not appropriate because RDTs measure antigen levels, whereas microscopy measures parasite densities; therefore, exact congruence is not possible for the RDT. Additionally, many false positives attributed to RDTs are actually true positives, and merely reflect the tremendous sensitivity of the RDT. BinaxNOW® compared with other RDTs fared well in assessments of Plasmodium falciparum (P. falciparum) sensitivity, but was considered subpar when analyzed for its P. vivax
The safety of making clinical management decisions solely on RDT test results was also addressed by Dr. D'Acremont. She presented data from numerous studies which demonstrated that no adverse outcomes were associated with false negative RDT results in nearly 10,000 children. 7, 8, 9 In returning travelers suspected of malaria, RDT-based algorithms in the setting of delayed (i.e., next day) microscopy demonstrated that clinical decisions could safely be made based solely on RDT results.
One reason motivating the use of RDTs for confirmatory testing for malaria is the need to reduce the amount of anti-malarial medication being erroneously prescribed, to reduce the selective pressures driving anti-malarial drug resistance. The impact of RDT implementation on malaria drug consumption in endemic countries has been profound. Implementation of an RDT in Tanzania was piloted in three district hospitals, three healthcare centers, and three dispensaries from 2006 to 2008. Prescriptions for anti-malarial medications significantly decreased from 81% to 24%. Unfortunately, antibiotic prescriptions increased modestly from 49% to 73%, indicating that, although RDTs provided 5 Ochola LB, Vounatsou P, Smith T, et al. The reliability of diagnostic techniques in the diagnosis and management of malaria in the absence of a gold standard. Lancet Infect Dis. 2006; 6(9) : 582-588. healthcare workers with a more solid understanding of which patients did not have malaria, providers were still inclined to dispense medications without any evidence of microbial infection.
10
Prior to the DoD Stakeholder Meeting, a multi-disciplinary group of experts convened to explore and scrutinize available options to address the perceived RDT shortcomings. CDR Von Thun elaborated upon the "Possible Diagnostic Solutions for the RDT Capability," noting that there are two major types of approaches: packaging solutions and performance solutions. Packaging solutions could include changing manufacturer packaging such that fewer tests are included in each box, thereby reducing the footprint of the package (5-pack box already manufactured and available OCONUS); changing kit contents to make more operational friendly (to include lancets, multiple reagent bottles, etc.); and incorporating an external positive control to meet operational needs (CDC has dried cultured blood product that is temperature stable). Additionally, it was proposed that the package insert could be clarified to reflect DoD field use (i.e., microscopy at next available opportunity or echelon of care). A precedent has already been set with the Japanese Encephalitis vaccine which has both civilian and DoD package inserts for the identically-manufactured product. These potential solutions would be considered relatively short-term alternatives in lieu of a more permanent, performance solution.
Performance solutions would address issues of the test's inferior sensitivity and could potentially include: reformatting and modernization of the existing BinaxNOW® RDT; selection, and bringing to market, of another COTS product; or development of a second-generation RDT. Modernization of an existing capability can address many of the post-marketing issues associated with BinaxNOW® and wouldn't require the creation of new requirement documents as would the other two alternatives-although all options would require additional clinical trials to document efficacy. Whereas developing a second-generation RDT would be a long-term process, revising the current RDT or bringing a new, first-generation RDT to market would provide a more intermediate solution.
Options and constraints pertaining to the Clinical Laboratory Improvement Program (CLIP) manual and CLIA waivers were clarified. The CLIP manual can be modified only as may be required to meet the unique aspects of DoD missions, according to DODI 6440.2 [Appendix F]; however, CAPT Wilkerson (TMA/OCMO) explained that there is no such thing as a waiver of CLIA requirements. A "CLIA waiver" is a package that a vendor submits to the FDA in order to request that a moderate complexity device be placed in a "waived category" regarding restrictions of use for that device or test. In DoD's agreement with the U.S. Department of Health and Human Services (DHHS), CLIA regulations are implemented via CLIP, and a lab is defined as a person, place, or locale that is conducting medical diagnostic work to provide a result to a clinician to make a clinical diagnostic decisions.
Another participant noted that only force health protection (FHP) issues were required to abide by FDA regulations. Any universal FHP measures, such as required medications or required vaccinations, must abide by FDA on-label instructions; however, the practice of medicine in an individual patientprovider relationship is not beholden to FDA regulations because individual patient care would no longer be considered part of a FHP directive.
Mr. Lou Jasper from USAMMDA led the culminating discussion on "Defining the Requirements for RDTs." The goal of the discussion was to determine how best to address the gaps identified throughout the 2012 Stakeholder Meeting and to ensure that the proposed solutions meet the field requirements and receive the necessary attention from DoD policy makers. The ultimate objective is to be able to provide a field-expedient rapid diagnostic capability that offers suitable sensitivity, robustness (with positive controls), and environmental stability. The rapid diagnostic capability must also be able to be utilized at the level of the medic, corpsman, and technician. With this objective in mind, participants of the 2012 Stakeholder Meeting recommended:
(a) All affected CCMD Surgeons will draft a letter to be vetted to USAMRMC stating the importance of approving a rapid diagnostic product that can be used for malaria diagnosis in the field by individuals with minimal medical expertise; (b) A working group should be established to determine whether a materiel or non-materiel solution is required to field an RDT. This working group should consist of a technician-based human diagnostics IPT with the addition of subject matter experts to contribute to a survey that will help refine the need for an RDT.
Conclusions and Way Forward
There are many facets to the DoD malaria prevention program, with each of the various communities playing essential but unique roles. This 2012 DoD Malaria Stakeholder Meeting brought together numerous Service, specialty, COCOM and operational experts including representatives from the public health, preventive medicine, infectious disease, entomology, pest management, education and training, laboratory, materiel and acquisitions, and research and development communities. These Stakeholders convened to strategize how best to improve and optimize the DoD's malaria program.
Many of the initiatives addressed in this forum are currently in the development and implementation phases. The Armed Forces Pest Management Board is addressing PPM compliance through a media campaign and utilization of new technologies, particularly given the tech-savvy aptitude of our younger Service members. The Armed Forces Infectious Disease Society will publish their DoD Malaria/Febrile Patient Clinical Practice Guideline which serves as a clinical resource to deployed providers. The Defense Health Clinical Center's PDHealth website has been designated as the central DoD repository for malaria resources and will host a Tri-Service board of advisors to supervise content posted to their malaria webpage. Microscopy diagnostic training aids, developed by the DoD overseas laboratories, are being incorporated into the enlisted and laboratory officer training curricula. As the deliberations continue regarding a revision to the chemoprophylaxis policy (drafted in 2011), issues regarding appropriate primaquine dosing will need to be addressed.
However, the way ahead in providing more expeditionary diagnostic capabilities to the deployed medical providers in theater still needs to be elucidated. The desired output from this meeting is securing support for a rapid diagnostic product that the medics and corpsmen can use for diagnoses of malaria in a forward deployed capacity without the need for microscopy confirmation. This series of Malaria Stakeholder Meetings has provided the opportunity to address many operationally relevant issues and has benefited from having critical stakeholders in attendance. Attendees were enthusiastic about the progress made at these meetings; strategies have been outlined for each of the topics, and stakeholders are continuing to work independently to capitalize upon the momentum generated. Certainly there are growth opportunities still to be realized, but it is hoped that these conversations and ongoing efforts have had impact and will result in significant progress in further meeting the needs of our warfighters and deployed medical personnel with the objective of diminishing the impact of malaria on U.S. Forces. 
Diagnosis and Management of Malaria in U.S. Military Personnel in Resource Limited
EXECUTIVE SUMMARY
Military service members deployed to malaria endemic areas are a subset of travelers with significant exposure to the risk of malaria. Despite current Department of Defense policy and provision of personal-protective measures and medicinal prophylaxis for service members operating in endemic regions, malaria continues to affect a significant proportion of at-risk service members. Military members should have access to recommended regimens for the treatment of malaria; however instances do occur where severe disease occurs in settings where resources are limited, diagnosis is difficult, and needed U.S. Food and Drug Administration (FDA) approved medications are scarce. Military healthcare providers should therefore be familiar with WHO-endorsed diagnostics and treatments available in malaria-endemic countries in situations where these services are needed while awaiting evacuation of a service member to a higher level military treatment facility. These guidelines provide recommendations for preparation and training prior to deployment to a malaria endemic area as well as evaluation, treatment, and management of a febrile service member at risk of malaria.
Each section begins with a question and is followed by numbered recommendations from the panel with strength and quality of supporting evidence ratings (Table 1) . Treatment tables and algorithms are provided to guide use of these recommendations. Recommendations are supported by the evidence based review that follows the Executive Summary.
